Bridging EGFR/TGF-β Signaling to Bypass Resistance to Immune Checkpoint Blockade
Although EGFR is a common target in squamous cancers, anti-EGFR monotherapies have shown modest success because of existing or acquired activation of other oncogenic pathways and tumor heterogeneity. A bifunctional fusion protein ficerafusp alfa in combination with pembrolizumab represents a potential solution to overcome resistance in early-phase clinical investigation. See related article by Hernando-Calvo et al., p. 4623.
Authors
- Natalia Issaeva (ORCID: https://orcid.org/0000-0001-5483-6610)
- Noura J. Choudhury (ORCID: https://orcid.org/0000-0002-5980-4973)
- Christine M. Bestvina (ORCID: https://orcid.org/0000-0001-7189-1590)
- Aditi Kothari (ORCID: https://orcid.org/0000-0003-0416-0565)
Institutions
- University of North Carolina at Chapel Hill (US)
- University of Chicago (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2727
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00